Transgenomic PRPO 深 沪
等待开盘 10-13 09:30:00 美东时间
19.038
-0.622
-3.16%
华盛通- 最 高20.614
- 今 开20.614
- 成交量 8731股
- 最 低 18.85
- 昨 收 19.66
- 总市值 2878.55万
- 52周最高 22.3825
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 3.90
- 委 比 90.48%
- 总股本 151.20万
- 历史最高 8448.00
- 量 比 0.54
- 振 幅 8.97%
- 历史最低 3.90
- 每 手 1
- 风险率 4.48%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Precipio Terminates Its ATM
Specialty cancer diagnostics company Precipio, Inc. has terminated its At-The-Market (ATM) instrument with investment bank Alliance Global Partners (AGP). CEO Ilan Danieli stated that the company is in a stronger financial position now, with positive cash flow and increased cash reserves, making the ATM tool unnecessary for capital raises. This move reflects management's commitment to responsible capital management and creating shareholder value.
09-02 14:00
Precipio Unveils Advancements in AML Diagnostic Technology
The latest announcement is out from Precipio ( ($PRPO) ). On August 18, 2025, P...
08-19 05:32
Precipio Q2 EPS $0.05 Up From $(0.83) YoY, Sales $5.654M Up From $4.441M YoY
Precipio (NASDAQ:PRPO) reported quarterly earnings of $0.05 per share. This is a 106.02 percent increase over losses of $(0.83) per share from the same period last year. The company reported $5.654 million in sales this
08-14 05:05
Precipio Announces its Q2-2025 Financial Results
<p>Precipio Inc., a specialty cancer diagnostics company, reported Q2-2025 financial results with $5.7M in revenue, a 27% YoY and 15% QoQ increase. Adjusted EBITDA improved to $(78K) from $(609K) YoY. Cash flow used decreased 71% YoY. Both product and pathology services divisions showed strong growth, with gross margins improving to 43% overall. The company expects to end the year debt-free and cash flow positive. A conference call is scheduled f...
08-13 21:00
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Sonnet BioTherapeutics (NASDAQ:SONN) shares rose 239.4% to $17.55 dur...
07-14 20:08
Precipio Revises Warrant Agreement With Largest Holder; 100K To Be Exercised For Cash, 200K Through Cashless Conversion
Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO) has entered into an agreement with its largest warrant holder, amending the existing structure from cash exercise of warrants, to a revised
07-12 04:33
Precipio Enters Into Agreement With Warrant Holder To Exercise Majority Of Warrants As Cashless
Precipio, Inc. (NASDAQ: PRPO) has amended its warrant agreement with its largest warrant holder, modifying the cash exercise structure. Under the new terms, 100,000 warrants (about one-third) will be exercised with cash, yielding approximately $1.2 million, while the remaining 200,000 warrants will be exercised cashlessly. This reduces the total shares added to ~130,000-150,000 from ~300,000. Management will discuss the transaction further during...
07-11 20:30
Precipio is requesting Shareholders/Brokers vote today to avoid costly adjournment and rescheduling of Annual Shareholders Meeting
Precipio, Inc., a specialty cancer diagnostics company, is urging shareholders to vote their shares by June 16, 2025, at 11 p.m. Eastern Time to ensure a quorum for the upcoming shareholder meeting on June 17, 2025. Currently, 42% of shares have been voted, and at least 50% are needed to hold the meeting. Failing to meet the quorum could result in rescheduling costs as high as $100,000. Precipio develops innovative cancer diagnostic solutions to ...
06-16 16:00
Precipio Schedules Q1-2025 Shareholder Update Call
An update from Precipio ( ($PRPO) ) is now available. On May 1, 2025, Precipio,...
05-07 04:59
